Shilpa Medicare Ltd
Shilpa Medicare Ltd (SHILPAMED) last reported results for the quarter ended Jun 2026, with sales of ₹466 crore and net profit of ₹101 crore. The stock last traded at ₹1,062, a market capitalisation of ₹20,770 crore, on a P/E of 73.1. Over the past 52 weeks the stock has ranged between ₹260 and ₹1,096. Figures are as of 6 Oct 2026 and are not real time.
Shilpa Medicare Ltd share price and key metrics
- Current price
- ₹1,062
- Market cap
- ₹20,770 cr
- Stock P/E
- 73.1
- Book value
- ₹132
- ROE
- 8.99%
- ROCE
- 10.9%
- Dividend yield
- 0.06%
- 52w high / low
- 1096/260
Metrics as of 6 Oct 2026. Not real time.
Track Shilpa Medicare Ltd
Cruxal reads every Shilpa Medicare Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Shilpa Medicare Ltd growth and returns
- 10 Years
- 8%
- 5 Years
- 11%
- 3 Years
- 14%
- TTM
- 28%
- 10 Years
- 8%
- 5 Years
- 17%
- 3 Years
- 107%
- TTM
- 117%
- 10 Years
- 14%
- 5 Years
- 29%
- 3 Years
- 81%
- 1 Year
- 173%
- 10 Years
- 6%
- 5 Years
- 4%
- 3 Years
- 5%
- Last Year
- 9%
Shilpa Medicare Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹466 cr, up 45.2% from ₹321 cr a year earlier. Net profit was ₹101 cr, up 114.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 344 | 319 | 331 | 321 | 370 | 410 | 437 | 466 |
| Expenses | 258 | 239 | 252 | 231 | 262 | 296 | 317 | 330 |
| Operating profit | 86 | 81 | 79 | 91 | 108 | 114 | 120 | 136 |
| OPM % | 25% | 25% | 24% | 28% | 29% | 28% | 27% | 29% |
| Other income | 5 | 2 | -21 | 6 | 2 | -13 | 45 | 9 |
| Interest | 26 | 12 | 14 | 19 | 16 | 11 | 14 | 12 |
| Depreciation | 28 | 29 | 29 | 29 | 30 | 30 | 31 | 35 |
| Profit before tax | 37 | 42 | 15 | 50 | 64 | 61 | 120 | 98 |
| Tax % | 51% | 24% | 5% | 5% | 32% | 27% | 10% | -3% |
| Net profit | 18 | 32 | 15 | 47 | 44 | 45 | 108 | 101 |
| EPS (₹) | 0.92 | 1.62 | 0.74 | 2.40 | 2.25 | 2.28 | 5.51 | 5.16 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Shilpa Medicare Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 779 | 789 | 733 | 908 | 899 | 1,141 | 1,046 | 1,146 | 1,281 | 1,535 | 1,683 |
| Operating profit | 165 | 155 | 148 | 219 | 181 | 202 | 99 | 239 | 319 | 435 | 479 |
| OPM % | 21% | 20% | 20% | 24% | 20% | 18% | 9% | 21% | 25% | 28% | 28% |
| Net profit | 104 | 103 | 110 | 155 | 146 | 61 | -31 | 32 | 78 | 243 | 297 |
| EPS (₹) | 6.71 | 6.45 | 6.88 | 9.57 | 9.06 | 3.49 | -1.87 | 1.84 | 4.00 | 12.44 | 15.20 |
TTM is the trailing twelve months to the most recent quarter.
Shilpa Medicare Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 20 |
| Reserves | 979 | 1,077 | 1,189 | 1,321 | 1,471 | 1,814 | 1,775 | 1,800 | 2,353 | 2,572 |
| Borrowings | 241 | 191 | 194 | 390 | 846 | 683 | 798 | 937 | 588 | 660 |
| Other liabilities | 244 | 223 | 218 | 270 | 308 | 370 | 323 | 347 | 360 | 455 |
| Total liabilities | 1,472 | 1,499 | 1,610 | 1,989 | 2,632 | 2,876 | 2,904 | 3,093 | 3,311 | 3,706 |
| Fixed assets | 492 | 534 | 558 | 650 | 1,111 | 1,342 | 1,368 | 1,385 | 1,418 | 1,593 |
| CWIP | 141 | 210 | 429 | 666 | 541 | 506 | 655 | 719 | 822 | 884 |
| Investments | 253 | 140 | 2 | 10 | 21 | 34 | 43 | 40 | 35 | 58 |
| Other assets | 587 | 615 | 621 | 662 | 959 | 993 | 838 | 950 | 1,037 | 1,170 |
| Total assets | 1,472 | 1,499 | 1,610 | 1,989 | 2,632 | 2,876 | 2,904 | 3,093 | 3,311 | 3,706 |
As reported by the company. Total assets equal total liabilities by construction.
Shilpa Medicare Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 37 | 45 | 147 | 124 | 47 | 105 | 180 | 137 | 132 | 342 |
| Cash from investing | -257 | -10 | -196 | -290 | -404 | -286 | -232 | -171 | -198 | -339 |
| Cash from financing | 313 | -61 | 10 | 176 | 436 | 83 | 46 | 47 | 63 | 14 |
| Net cash flow | 93 | -26 | -39 | 10 | 79 | -98 | -7 | 13 | -3 | 17 |
| Free cash flow | -79 | -92 | -151 | -220 | -302 | -226 | -46 | -48 | -111 | -28 |
| CFO / operating profit | 43% | 55% | 123% | 76% | 52% | 69% | 215% | 74% | 56% | 93% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Shilpa Medicare Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 14% | 10% | 9% | 12% | 8% | 6% | 1% | 5% | 8% | 11% |
| Debtor days | 80 | 102 | 101 | 99 | 88 | 124 | 113 | 125 | 126 | 123 |
| Inventory days | 187 | 194 | 266 | 298 | 427 | 338 | 280 | 309 | 309 | 291 |
| Days payable | 110 | 106 | 115 | 122 | 91 | 139 | 125 | 156 | 93 | 113 |
| Cash conversion cycle | 157 | 189 | 253 | 275 | 425 | 323 | 268 | 278 | 342 | 301 |
| Working capital days | 79 | 98 | 98 | 68 | 72 | 77 | -13 | 48 | 80 | 51 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Shilpa Medicare Ltd shareholding pattern
Promoters held 40.13% at Jun 2026, down from 44.23% at Jun 2025. FIIs 11.39% and DIIs 8.05%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 44.33% | 44.23% | 44.23% | 44.23% | 44.23% | 40.13% | 40.13% | 40.13% |
| FIIs | 9.59% | 9.90% | 10.97% | 11.19% | 10.92% | 10.97% | 11.07% | 11.39% |
| DIIs | 8.18% | 8.27% | 7.55% | 7.46% | 7.67% | 8.34% | 8.58% | 8.05% |
| Public | 37.90% | 37.59% | 37.25% | 37.10% | 37.18% | 40.56% | 40.21% | 40.42% |
| No. of shareholders | 42,784 | 49,034 | 50,108 | 48,636 | 52,065 | 53,799 | 53,410 | 60,926 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Shilpa Medicare Ltd corporate filings
- Europe GMP approval granted to Shilpa Medicare Ltd. Unit 4, Jadcherla, TelanganaCompany Updatelow impact
Cruxal's analysis: Shilpa Medicare Ltd. received European GMP approval for its Unit 4 located in Jadcherla…
Read the full analysis - Compliance Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018Company Updatelow impact
- Shilpa Medicare Limited: Promoter Group releases 30 lakh equity shares from pledgeInsider Trading / SASTmedium impact
Cruxal's analysis: Shilpa Medicare Limited has announced that members of its Promoter Group have released an…
Read the full analysis - Intimation of Closure of Trading WindowInsider Trading / SASTlow impact
- Shilpa Medicare receives ESG rating from CRISIL ESG RatingsCompany Updatelow impact
Cruxal's analysis: Shilpa Medicare Ltd has announced the assignment of an ESG rating by CRISIL ESG Ratings…
Read the full analysis - Shilpa Medicare Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Shilpa Medicare Ltd has issued an intimation regarding a scheduled meeting with analysts…
Read the full analysis - Shilpa Medicare reports USFDA inspection of Unit VII, Analytical Services Division, HyderabadCompany Updatemedium impact
Cruxal's analysis: Shilpa Medicare has disclosed a USFDA inspection at its Unit VII facility, which houses…
Read the full analysis - Shilpa Medicare Limited concludes 39th AGM; shareholders approve final dividend of INR 0.60 per shareAGM/EGMlow impact
Cruxal's analysis: Shilpa Medicare Limited has successfully concluded its 39th Annual General Meeting, with…
Read the full analysis - Shilpa Medicare receives SEC approval for Ondansetron Extended-Release Injection (100 mg/mL)Company Updatemedium impact
Cruxal's analysis: Shilpa Medicare has received final approval from the Subject Expert Committee (SEC) for…
Read the full analysis - Shilpa Medicare Limited Concludes 39th AGM; Declares Dividend of 0.60 INR Per ShareAGM/EGMlow impact
Cruxal's analysis: Shilpa Medicare Limited has successfully concluded its 39th Annual General Meeting held…
Read the full analysis - Shilpa Medicare's wholly owned subsidiary FTF Pharma faces NCLT-ordered insolvency resolution processCompany Updatehigh impact
Cruxal's analysis: Shilpa Medicare Limited has disclosed that the National Company Law Tribunal (NCLT)…
Read the full analysis - Shilpa Medicare Ltd initiates communication to shareholders for email registrationCompany Updatelow impact
Cruxal's analysis: Shilpa Medicare Ltd has initiated the dispatch of letters to shareholders who have not…
Read the full analysis - Shilpa Medicare clarifies recall of over 27,000 vials of chemotherapy drug in US marketCompany Updatemedium impact
Cruxal's analysis: Shilpa Medicare has issued a formal response to media reports regarding the recall of…
Read the full analysis - Shilpa Medicare Limited Announces Record Date and TDS Procedures for Final Dividend of INR 0.60 per Share Corp Actionlow impact
Cruxal's analysis: Shilpa Medicare Limited has issued a formal communication to shareholders regarding the…
Read the full analysis - Shilpa Medicare Ltd: Routine Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: Shilpa Medicare Ltd has fulfilled its regulatory obligation under Regulation 30 of the…
Read the full analysis - Shilpa Medicare Limited releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Shilpa Medicare Limited has filed its Annual Report for the financial year 2025-26 as per…
Read the full analysis - Shilpa Medicare Limited announces 39th AGM for September 11, 2026, proposing final dividend of INR 0.60 per shareAGM/EGMlow impact
Cruxal's analysis: Shilpa Medicare Limited has issued a notice for its 39th Annual General Meeting (AGM) to…
Read the full analysis - Shilpa Medicare Reports Record Q1 FY27 Financials with 43% Revenue Growth and 115% PAT SurgeCompany Updatehigh impact
Cruxal's analysis: Shilpa Medicare Limited delivered a strong performance in Q1 FY27, reporting record…
Read the full analysis - Shilpa Medicare Ltd releases audio recording of Q1 FY27 investor conference callCompany Updatelow impact
Cruxal's analysis: Shilpa Medicare has provided the audio link for the investor conference call held…
Read the full analysis - Shilpa Medicare Reports Strong 1QFY27 Results with 43% YoY Revenue Growth and 115% YoY PAT SurgeCompany Updatehigh impact
Cruxal's analysis: Shilpa Medicare Limited delivered robust 1QFY27 financial results, reporting revenue of…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.